| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 18
| Issue : 2 | Page : 461-469 |
|
|
Meta-analysis of the efficacy of glycyrrhizin for postoperative liver preservation in patients with liver cancer
Yongqing Li1, Mingju Hao2, Bingyang Zhang2, Peijun Wang1, Dantong Zhang3, Sumei Lu2, Wanshan Ma2
1 Department of Laboratory Medicine, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong, P. R. China
2 Department of Laboratory Medicine, Shandong Provincial Qianfoshan Hospital, Shandong University; Department of Laboratory Medicine, The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, P. R. China
3 Department of Laboratory Medicine, The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, P. R. China
Correspondence Address:
Sumei Lu
Department of Laboratory Medicine, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014; Department of Laboratory Medicine, The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong 250014
P. R. China
Wanshan Ma
Department of Laboratory Medicine, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014; Department of Laboratory Medicine, The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong 250014
P. R. China
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jcrt.jcrt_1811_21
|
|
|
Objective: This meta-analysis comprehensively summarizes the current clinical research on compound glycyrrhizin (CG) treatment for liver cancer and protecting liver function to guide clinical treatment.
Methods: Eighteen English-language articles were retrieved from PubMed, SinoMed, Cochrane, Embase, Web of Science, and three Chinese databases: The Wan Fang database, China National Knowledge Infrastructure (CNKI), and the VIP database.
Results: CG treatment improved the patient's alanine aminotransferase (ALT) level (in the metastatic liver cancer group: mean deviation (MD) = −13.78, 95% confidence interval (CI) = [−17.29, 10.27]; in the primary liver cancer group: MD = −32.15, 95% CI = [−35.48, 28.81]); aspartate aminotransferase (AST) level (in the primary liver cancer group: MD = −21.63, 95% CI = [−24.29, 18.96]; in the metastatic liver cancer group: MD = −15.64, 95% CI = [−19.08, −12.20]); serum total bilirubin (TBIL) level (MD = −1.61, 95% CI = [−2.71, −0.51]); and serum albumin (ALB) level (MD = 2.80, 95% CI = [1.85, 3.74]). CG treatment was efficient than the control (relative risk [RR] = 1.66, 95% CI = [1.35, 2.04]). Although adverse reactions, including fever, were higher than in the control group (RR = 1.13, 95% CI = [0.89, 1.43]), they were controllable.
Conclusion: CG affects liver preservation in treating liver cancer, which can reduce ALT, AST, and TBIL levels in patients; increase the ALB level; and protect liver cells. The CG-treated group showed improvement compared with the control group; although adverse reactions occurred in the treated group, the duration was shortened.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
|
|
| Article Access Statistics | | | Viewed | 214 | | | Printed | 6 | | | Emailed | 0 | | | PDF Downloaded | 24 | | | Comments | [Add] | | |
|
|
